Half-year report · HY
4361.TEDINET S100YP26
Period2025-12-01 → 2026-05-31
Filed2026-07-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.3bn | 2025-12-01 → 2026-05-31 | Cons. | Net sales |
| Revenue | ¥8.8bn | 2024-12-01 → 2025-11-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.3bn | 2024-12-01 → 2025-05-31 | Cons. | Net sales |
| Operating income | ¥304m | 2025-12-01 → 2026-05-31 | Cons. | Operating income |
| Operating income | ¥199m | 2024-12-01 → 2025-05-31 | Cons. | Operating income |
| Ordinary income | ¥285m | 2025-12-01 → 2026-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥405m | 2024-12-01 → 2025-11-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥183m | 2024-12-01 → 2025-05-31 | Cons. | Ordinary income |
| Profit before tax | ¥288m | 2025-12-01 → 2026-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥183m | 2024-12-01 → 2025-05-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥209m | 2025-12-01 → 2026-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥298m | 2024-12-01 → 2025-11-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥135m | 2024-12-01 → 2025-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥209m | 2025-12-01 → 2026-05-31 | Cons. | Profit loss |
| Net income | ¥135m | 2024-12-01 → 2025-05-31 | Cons. | Profit loss |
| Total assets | ¥9.0bn | at 2026-05-31 | Cons. | Assets |
| Total assets | ¥8.9bn | at 2025-11-30 | Cons. | Assets |
| Total assets | ¥8.8bn | at 2025-05-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.7bn | at 2026-05-31 | Cons. | Liabilities |
| Total liabilities | ¥5.7bn | at 2025-11-30 | Cons. | Liabilities |
| Net assets / equity | ¥3.3bn | at 2026-05-31 | Cons. | Net assets |
| Net assets / equity | ¥3.1bn | at 2025-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.9bn | at 2025-05-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.0bn | at 2026-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.2bn | at 2025-11-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.0bn | at 2026-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.2bn | at 2025-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2025-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥745m | at 2024-11-30v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.1bn | 2025-12-01 → 2026-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥830m | 2024-12-01 → 2025-11-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥566m | 2024-12-01 → 2025-05-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥138m | 2025-12-01 → 2026-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥739m | 2024-12-01 → 2025-11-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥216m | 2024-12-01 → 2025-05-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥228m | 2025-12-01 → 2026-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥360m | 2024-12-01 → 2025-11-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥187m | 2024-12-01 → 2025-05-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥171.92 | 2025-12-01 → 2026-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥245.11 | 2024-12-01 → 2025-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥110.52 | 2024-12-01 → 2025-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 36.6% | at 2026-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.3% | at 2025-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.5% | at 2025-05-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| Pharmaceutical Productsreportable segment | revenue | 2025-12-01 → 2026-05-31 | ¥4.3bn |
| Pharmaceutical Productsreportable segment | revenue external | 2025-12-01 → 2026-05-31 | ¥4.3bn |
| Pharmaceutical Productsreportable segment | segment profit | 2025-12-01 → 2026-05-31 | ¥288m |
| Real Estate Leasingreportable segment | revenue | 2025-12-01 → 2026-05-31 | ¥19m |
| Real Estate Leasingreportable segment | revenue external | 2025-12-01 → 2026-05-31 | ¥19m |
| Real Estate Leasingreportable segment | segment profit | 2025-12-01 → 2026-05-31 | ¥15m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-12-01 → 2026-05-31 | ¥4.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-12-01 → 2026-05-31 | ¥4.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-12-01 → 2026-05-31 | ¥304m |
| Pharmaceutical Productsreportable segment | revenue | 2024-12-01 → 2025-05-31 | ¥4.3bn |
| Pharmaceutical Productsreportable segment | revenue external | 2024-12-01 → 2025-05-31 | ¥4.3bn |
| Pharmaceutical Productsreportable segment | segment profit | 2024-12-01 → 2025-05-31 | ¥184m |
| Real Estate Leasingreportable segment | revenue | 2024-12-01 → 2025-05-31 | ¥19m |
| Real Estate Leasingreportable segment | revenue external | 2024-12-01 → 2025-05-31 | ¥19m |
| Real Estate Leasingreportable segment | segment profit | 2024-12-01 → 2025-05-31 | ¥15m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-12-01 → 2025-05-31 | ¥4.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-12-01 → 2025-05-31 | ¥4.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-12-01 → 2025-05-31 | ¥199m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 480
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | InterimDuration | 4315008000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E01006-000PharmaceuticalProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E01006-000RealEstateLeasingReportableSegmentMember | － | JPY |
| Transactions with other segments | InterimDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | InterimDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | InterimDuration | － | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E01006-000PharmaceuticalProductsReportableSegmentsMember | 4295725000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E01006-000RealEstateLeasingReportableSegmentMember | 19283000 | JPY |
| Net sales | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 4315008000 | JPY |
| Net sales | InterimDuration_ReconcilingItemsMember | － | JPY |
| Net sales | InterimDuration | 4315008000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E01006-000PharmaceuticalProductsReportableSegmentsMember | 288402000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E01006-000RealEstateLeasingReportableSegmentMember | 15413000 | JPY |
| Operating income | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 303815000 | JPY |
| Operating income | InterimDuration_ReconcilingItemsMember | － | JPY |
| Operating income | InterimDuration | 303815000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2026-07-10 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第125期中(自 2025年12月１日 至 2026年５月31日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)川口化学工業株式会社 | |
| Company name in english cover page | FilingDateInstant | Kawaguchi Chemical Industry Co., Ltd | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 山 田 秀 行 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都千代田区内神田２丁目８番４号(同所は登記上の本店所在地であり、実際の業務は、下記で行っております。) | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | － | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | － | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)本社事務所 埼玉県川口市領家４丁目６番42号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 048(222)5171 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役経理部長 本 間 義 隆 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E01006 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 43610 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)川口化学工業株式会社 | |
| Filer name in english | FilingDateInstant | Kawaguchi Chemical Industry Co., Ltd | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2025-12-01 | |
| Current period end date | FilingDateInstant | 2026-05-31 | |
| Type of current period | FilingDateInstant | HY | |
| Current fiscal year end date | FilingDateInstant | 2026-11-30 | |
| Previous fiscal year start date | FilingDateInstant | 2024-12-01 | |
| Comparative period end date | FilingDateInstant | 2025-05-31 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |